St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today presented favorable results from the largest observational study to date of the company’s AMPLATZER™ Amulet™ left atrial appendage (LAA) occluder. The data were presented in a Late Breaking Clinical Trial session at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington, D.C.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161102005979/en/
The St. Jude Medical(TM) AMPLATZER(TM) Amulet(TM) device is used to completely seal off the left atrial appendage (LAA) in patients diagnosed with non-valvular atrial fibrillation (AF). Sealing off the LAA in patients with AF may prevent the risk of blood clot formation and release, potentially reducing that risk. (Photo: St. Jude Medical)
The prospective, multicenter, international AMPLATZER Amulet Observational Study of LAA occlusion (closure) enrolled 1,073 patients at 64 centers across 18 countries. Initial results from the study showed a 98.8 percent implant success rate adding to the clinical evidence that the AMPLATZER Amulet LAA Occluder is a safe alternative for prevention of stroke in patients with non-valvular atrial fibrillation (AF).
The AMPLATZER Amulet LAA Occluder is used to close the LAA (an appendage of the left atrium) in patients diagnosed with non-valvular AF. Atrial fibrillation occurs when the upper chambers of the heart (atria) contract rapidly and irregularly, which can disrupt efficient pumping of the blood out of the heart. Blood that pools in the atria can clot and, if the clot moves to an artery in the brain, stroke may occur. Studies have shown that AF can dramatically increase the risk of stroke for patients and for many patients, medication has historically been the option physicians turn to most often.
“Patients with atrial fibrillation at risk of stroke are usually prescribed anticoagulant medication, but this treatment comes with some limitations. Patients might not tolerate the medication, plus there’s a risk for major bleeding,” said Dr. David Hildick-Smith from Sussex Cardiac Centre at Brighton and Sussex University Hospitals Brighton, United Kingdom and principal investigator of the AMPLATZER Amulet Observational Study. “By closing the LAA with the AMPLATZER Amulet device, physicians can seal off the LAA, with the objective of reducing the risk of stroke and eliminating the need for oral anticoagulants.”
Other key findings of the Amulet Observational study include:
“Initial data from this large-scale observational study continue to affirm the AMPLATZER Amulet LAA Occluder as an important treatment option to reduce the risk of stroke in patients with non-valvular AF,” said Dr. Srijoy Mahapatra, medical director and vice president of medical affairs at St. Jude Medical. “The AMPLATZER Amulet Occluder has favorable closure rates when compared to other device reports in a similar patient group.”
The AMPLATZER Amulet Left Atrial Appendage Occluder is CE Mark approved, but remains an investigational device in the United States. In September, St. Jude Medical announced the start of the AMPLATZER™ Amulet™ LAA Occluder IDE trial, evaluating the safety and effectiveness of the company’s AMPLATZER Amulet occluder device. The trial will enroll patients at up to 100 sites in the United States and an additional 50 sites internationally.
The shape and size of an LAA can vary greatly. The AMPLATZER Amulet LAA Occluder has a conformable disc and lobe designed for complete occlusion of the LAA and offers the broadest size range available. The device offers physicians options to help meet the anatomical demands of patients in need of LAA closure.
About Atrial Fibrillation and Stroke
During AF, chaotic electrical signals in the heart’s upper chambers (atria) beat erratically and out of sync with the two lower chambers, resulting in poor blood flow. The LAA is a tube-shaped appendage connected to the left atrium of the heart that can potentially hold static blood during an episode of AF, increasing the likelihood of clot formation. Research shows that in AF patients, approximately 90 percent of all cardiac blood clots form in the LAA. If a clot forms in the LAA and is then released into the heart, it may enter blood circulation, travel to the brain, block a vessel and cause an ischemic stroke. The current standard of care to treat ischemic stroke in AF patients is blood-thinning medications, which comes with major, sometimes fatal, bleeding risks.
According to the World Health Organization (WHO), an estimated 15 million strokes occur worldwide each year. In 2010, stroke cost the United States an estimated $53.9 billion in health care services, medications and missed days of work.
About St. Jude Medical
St. Jude Medical is a leading global medical device manufacturer and is dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases. The company does this by developing cost-effective medical technologies that save and improve lives of patients around the world. Headquartered in St. Paul, Minn., St. Jude Medical has five major areas of focus that include heart failure, atrial fibrillation, neuromodulation, traditional cardiac rhythm management, and cardiovascular. For more information, please visit sjm.com or follow us on Twitter @SJM_Media.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the company, including potential clinical successes, reimbursement strategies, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the company’s control and the risk factors and other cautionary statements described in the company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2016 and Quarterly Report on Form 10-Q for the fiscal quarter ended July 2, 2016. The company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161102005979/en/Business Wire
Last updated on: 02/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.